atezolizumab

atezolizumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Small Cell Lung Cancer (SCLC)、Extensive-stage Small Cell Lung Cancer (ES-SCLC)。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 atezolizumab 研究

• Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

  早期 I 期招募中中国NCT07538128

• Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

  II 期招募中美国NCT05538091

• Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial

  II 期招募中美国NCT05333458

• DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer

  I 期招募中美国NCT07545954

• Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

  II 期招募中加拿大NCT04273061

• Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

  II 期招募中美国NCT04919382

• Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

  II 期招募中意大利NCT07276100

• Adebrelimab + Apatinib in SCLC Maintenance Therapy

  II 期招募中中国NCT06475209

• Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma

  II 期招募中中国台湾NCT06339424

• Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

  II 期招募中RussiaNCT07130032

• JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors

  不适用招募中法国NCT04294771

• Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

  I 期 / II 期招募中美国NCT06110572

• DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

  II 期 / III 期招募中英国NCT05770102

• Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

  II 期招募中中国台湾NCT06133062

• Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial

  II 期招募中中国NCT05751343

• Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

  II 期招募中意大利NCT06690840

• A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

  II 期招募中美国NCT04302025

• Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

  III 期招募中美国澳大利亚奥地利比利时NCT05549297

• Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

  I 期 / II 期招募中比利时荷兰西班牙NCT04954599

• Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

  III 期招募中美国加拿大South KoreaNCT05317858

• A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

  I 期 / II 期招募中美国法国日本西班牙NCT06362252

• Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

  I 期 / II 期招募中美国NCT06439485

• A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

  I 期 / II 期招募中美国NCT05440708

• Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)

  II 期招募中西班牙NCT07153445

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。